New News information at Pharmaceutical Technology New and updated information from News listed on www.pharmaceutical-technology.com http://www.pharmaceutical-technology.com/ en-us http://www.pharmaceutical-technology.com/ New News information at Pharmaceutical Technology http://www.pharmaceutical-technology.com/content/images/logo_big.gif Selexis and OSE Immunotherapeutics to support OSE-127 (Effi-7) development http://www.pharmaceutical-technology.com/news/newsselexis-and-ose-immunotherapeutics-to-support-ose-127-effi-7-development-5822785 http://www.pharmaceutical-technology.com/news/newsselexis-and-ose-immunotherapeutics-to-support-ose-127-effi-7-development-5822785 Swiss-based Selexis has signed a commercial licence agreement to provide French biotechnology firm OSE Immunotherapeutics with access to high-performance research cell banks (RCBs) from its SUREtechnology Platform. Tue, 23 May 2017 23:00:00 GMT FDA approves Sanofi and Regeneron’s Kevzara for adult rheumatoid arthritis http://www.pharmaceutical-technology.com/news/newsfda-approves-sanofi-regenerons-kevzara-for-adult-rheumatoid-arthritis-5822982 http://www.pharmaceutical-technology.com/news/newsfda-approves-sanofi-regenerons-kevzara-for-adult-rheumatoid-arthritis-5822982 Sanofi and Regeneron Pharmaceuticals’ drug Kevzara (sarilumab) has received the US Food and Drug Administration (FDA) approval to treat adult patients affected with moderately to severely active rheumatoid arthritis (RA). Tue, 23 May 2017 23:00:00 GMT UK CMA accuses Merck of breaking competition law with discount scheme http://www.pharmaceutical-technology.com/news/newsuk-cma-accuses-merck-of-breaking-competition-law-with-discount-scheme-5822959 http://www.pharmaceutical-technology.com/news/newsuk-cma-accuses-merck-of-breaking-competition-law-with-discount-scheme-5822959 The UK Competition and Markets Authority (CMA) has accused US pharmaceutical company Merck Sharp & Dohme (MSD) of operating an anti-competitive discount scheme for its medicine Remicade. Tue, 23 May 2017 23:00:00 GMT Ardelyx’s first-in-class NHE3 blocker Tenapanor boasts positive phase III data http://www.pharmaceutical-technology.com/news/newsardelyxs-first-in-class-nhe3-blocker-tenapanor-boasts-positive-phase-iii-data-5823329 http://www.pharmaceutical-technology.com/news/newsardelyxs-first-in-class-nhe3-blocker-tenapanor-boasts-positive-phase-iii-data-5823329 On May 12, Ardelyx, a US-based clinical-stage company focused on the development of treatments for cardio-renal and gastrointestinal (GI) diseases, announced positive top-line results from the T3MPO-1 Phase III study for the use of tenapanor to treat… Tue, 23 May 2017 23:00:00 GMT Singapore eDevelopment subsidiary starts advanced research on Linebacker http://www.pharmaceutical-technology.com/news/newssingapore-edevelopment-subsidiary-initiates-advanced-research-on-linebacker-5821773 http://www.pharmaceutical-technology.com/news/newssingapore-edevelopment-subsidiary-initiates-advanced-research-on-linebacker-5821773 Singapore eDevelopment subsidiary Global BioLife has started advanced research on a new universal therapeutic drug platform called Linebacker to tackle multiple conditions such as Alzheimer's, diabetes, and cancer.  Mon, 22 May 2017 23:00:00 GMT AC Immune and Essex to develop biological treatment for neurodegenerative diseases http://www.pharmaceutical-technology.com/news/newsac-immune-essex-to-co-develop-biological-therapeutic-for-neurodegenerative-diseases-and-neuroinflammation-5821748 http://www.pharmaceutical-technology.com/news/newsac-immune-essex-to-co-develop-biological-therapeutic-for-neurodegenerative-diseases-and-neuroinflammation-5821748 AC Immune and Essex Bio-Technology have signed a research collaboration agreement to conduct a pre-clinical study and clinical codevelopment of a novel biological therapeutic to treat neurodegenerative diseases and neuroinflammation. Mon, 22 May 2017 23:00:00 GMT AstraZeneca signs deal to sell commercial rights for Seloken in Europe http://www.pharmaceutical-technology.com/news/newsastrazeneca-signs-deal-to-sell-commercial-rights-for-seloken-in-europe-5821761 http://www.pharmaceutical-technology.com/news/newsastrazeneca-signs-deal-to-sell-commercial-rights-for-seloken-in-europe-5821761 AstraZeneca has entered an agreement to provide the commercial rights for Seloken/Seloken ZOK (metoprolol tartrate and metoprolol succinate respectively) and associated Logimax fixed-dose combination (metoprolol succinate and felodipine) treatments i… Mon, 22 May 2017 23:00:00 GMT Sanofi’s insulin lispro receives CHMP positive opinion to treat diabetes http://www.pharmaceutical-technology.com/news/newssanofis-insulin-lispro-receives-chmp-positive-opinion-to-treat-diabetes-5819420 http://www.pharmaceutical-technology.com/news/newssanofis-insulin-lispro-receives-chmp-positive-opinion-to-treat-diabetes-5819420 The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorisation of Sanofi's insulin lispro. Sun, 21 May 2017 23:00:00 GMT Cancer Research UK funded scientists to test Zika virus on brain tumours http://www.pharmaceutical-technology.com/news/newscancer-research-uk-funded-scientists-to-test-zika-virus-on-brain-tumours-5820568 http://www.pharmaceutical-technology.com/news/newscancer-research-uk-funded-scientists-to-test-zika-virus-on-brain-tumours-5820568 Scientists funded by Cancer Research UK will investigate the effectiveness of the Zika virus in destroying brain tumour cells, which could lead to new treatments for cancer. Sun, 21 May 2017 23:00:00 GMT Merck’s Isentress receives CHMP positive opinion to treat HIV-1 infection http://www.pharmaceutical-technology.com/news/newsmercks-isentress-receives-chmp-positive-opinion-to-treat-hiv-1-infection-5820551 http://www.pharmaceutical-technology.com/news/newsmercks-isentress-receives-chmp-positive-opinion-to-treat-hiv-1-infection-5820551 Merck’s Isentress (raltegravir) 600mg film-coated tablets have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), for the treatment of HIV-1 infection in adults and paedi… Sun, 21 May 2017 23:00:00 GMT Deals this week: Shanghai Fosun Pharmaceutical Group, Shandong Buchang Pharmaceutical, 4SC http://www.pharmaceutical-technology.com/news/newsdeals-this-week-shanghai-fosun-pharmaceutical-group-co-ltd-shandong-buchang-pharmaceutical-co-ltd-4sc-ag-5817314 http://www.pharmaceutical-technology.com/news/newsdeals-this-week-shanghai-fosun-pharmaceutical-group-co-ltd-shandong-buchang-pharmaceutical-co-ltd-4sc-ag-5817314 Shanghai Fosun Pharmaceutical Group intends to raise approximately HK$2.32bn ($298.3m) through a private placement of 80.6 million shares. Thu, 18 May 2017 23:00:00 GMT M&As this week: Lonza Group, Shandong Buchang Pharmaceutical http://www.pharmaceutical-technology.com/news/newsmas-this-week-lonza-group-ltd-shandong-buchang-pharmaceutical-co-ltd-5817279 http://www.pharmaceutical-technology.com/news/newsmas-this-week-lonza-group-ltd-shandong-buchang-pharmaceutical-co-ltd-5817279 Swiss biopharmaceutical company Lonza Group has completed the acquisition of HansaBioMed Life Sciences OU, an Estonian pharmaceutical company. Thu, 18 May 2017 23:00:00 GMT NPPA issues notice to pharmaceutical firms for non-compliance of pricing provisions http://www.pharmaceutical-technology.com/news/newsnppa-issues-notice-to-pharmaceutical-firms-for-non-compliance-of-pricing-provisions-5818457 http://www.pharmaceutical-technology.com/news/newsnppa-issues-notice-to-pharmaceutical-firms-for-non-compliance-of-pricing-provisions-5818457 Indian drug price regulator the National Pharmaceutical Pricing Authority (NPPA) has issued notices to several pharmaceutical companies that have marketed combination drugs without complying Drug Price Control Order (DPCO) 2013. Thu, 18 May 2017 23:00:00 GMT Sobi receives SFDA approval for Orfadin capsules http://www.pharmaceutical-technology.com/news/newssobi-receives-sfda-approval-for-orfadin-capsules-5818417 http://www.pharmaceutical-technology.com/news/newssobi-receives-sfda-approval-for-orfadin-capsules-5818417 Specialist healthcare company Swedish Orphan Biovitrum (Sobi) has received approval from the Saudi Food and Drug Administration (SFDA) for Orfadin (nitisinone) capsules in strengths of 2mg, 5mg, 10mg and 20mg. Thu, 18 May 2017 23:00:00 GMT Bayer receives FDA priority review for copanlisib to treat follicular lymphoma http://www.pharmaceutical-technology.com/news/newsbayer-receives-fda-priority-review-for-copanlisib-to-treat-follicular-lymphoma-5817162 http://www.pharmaceutical-technology.com/news/newsbayer-receives-fda-priority-review-for-copanlisib-to-treat-follicular-lymphoma-5817162 German drug manufacturer Bayer has received priority review designation for the new drug application (NDA) for copanlisib from the US Food and Drug Administration (FDA). Wed, 17 May 2017 23:00:00 GMT X-Chem and Vertex form multi-target genetic disease collaboration http://www.pharmaceutical-technology.com/news/newsx-chem-and-vertex-form-multi-target-genetic-disease-collaboration-5817148 http://www.pharmaceutical-technology.com/news/newsx-chem-and-vertex-form-multi-target-genetic-disease-collaboration-5817148 US-based firms X-Chem and Vertex Pharmaceuticals have signed a collaboration agreement to discover new drug leads against targets involved in multiple speciality diseases. Wed, 17 May 2017 23:00:00 GMT ST Asia signs licensing agreement with PharmaMar for anti-cancer compound lurbinectedin http://www.pharmaceutical-technology.com/news/newsst-asia-signs-licensing-agreement-with-pharmamar-for-anti-cancer-compound-lurbinectedin-5817575 http://www.pharmaceutical-technology.com/news/newsst-asia-signs-licensing-agreement-with-pharmamar-for-anti-cancer-compound-lurbinectedin-5817575 Singapore-based biopharmaceutical company Specialised Therapeutics Asia (ST Asia) will commercialise a new anti-cancer compound known as lurbinectedin (PM1183) throughout South East Asia, following a second major licensing deal with Spanish pharmaceu… Wed, 17 May 2017 23:00:00 GMT Vifor Pharma and Akebia to sell Vadadustat to Fresenius Medical Care http://www.pharmaceutical-technology.com/news/newsvifor-pharma-and-akebia-to-sell-vadadustat-to-fresenius-medical-care-5816422 http://www.pharmaceutical-technology.com/news/newsvifor-pharma-and-akebia-to-sell-vadadustat-to-fresenius-medical-care-5816422 Vifor Pharma Group and Akebia Therapeutics have entered an exclusive licence agreement to sell Vadadustat to Fresenius Medical Care dialysis clinics located in the US after securing approval from the US Food and Drug Administration (FDA). Tue, 16 May 2017 23:00:00 GMT Boehringer opens biopharmaceutical manufacturing facility in China http://www.pharmaceutical-technology.com/news/newsboehringer-opens-biopharmaceutical-manufacturing-facility-in-china-5816455 http://www.pharmaceutical-technology.com/news/newsboehringer-opens-biopharmaceutical-manufacturing-facility-in-china-5816455 Germany’s Boehringer Ingelheim has officially opened its commercial production site for biopharmaceuticals in Zhang Jiang Hi-tech Park in Shanghai, China. Tue, 16 May 2017 23:00:00 GMT Cytokinetics receives FDA orphan drug status for Ck-2127107 to treat SMA http://www.pharmaceutical-technology.com/news/newscytokinetics-receives-fda-orphan-drug-status-for-ck-2127107-to-treat-sma-5816411 http://www.pharmaceutical-technology.com/news/newscytokinetics-receives-fda-orphan-drug-status-for-ck-2127107-to-treat-sma-5816411 Biopharmaceutical company Cytokinetics’ CK-2127107 has received orphan drug designation from the Office of Orphan Products Development of the US Food and Drug Administration (FDA) for the potential treatment of spinal muscular atrophy (SMA). Tue, 16 May 2017 23:00:00 GMT